Innovations in HIV treatment and care

posted on

More than 18 million people worldwide are accessing HIV treatment, and new World Health Organization (WHO) guidelines have dramatically expanded the number of people eligible to start treatment in many countries.

The 9th IAS Conference on HIV Science (IAS 2017) will showcase the latest innovations to meet the increased need for HIV care in a way that is both clinically effective and cost effective. Scientific highlights include:

  • 96-week results from MOBIDIP trial: Safety and efficacy of dual therapy as a second-line regimen
  • Real-world results from implementation of multi-month prescriptions for stable clients, including children and adolescents
  • New data on cost-effectiveness of community-based support for treatment adherence
  • Factors associated with falling outside the continuum of care among people who inject drugs
  • 48-week results from THILAO study: Efficacy of third-line treatment in a resource-limited setting
  • The effect of hepatitis C treatment on cause-specific mortality among people co-infected with HIV
  • Results from a pilot project of point-of-care testing for tuberculosis among hospitalized patients with HIV
  • Impact of antiretroviral treatment (ART) on pregnancy outcomes
  • Revelations from population-based surveys on the demographics most likely to fall outside of the 90-90-90 cascade


Programme highlights

Do we need triple therapy for everyone for life?
As an increasing amount of people with high CD4 cell count and low viral load are treated at an early stage of the disease, the treatment paradigm should be: controlled viral load in the plasma and controlled replication in the reservoirs, rather than lifelong triple therapy.

Integration of HIV with other care services
This session highlights successful models for integration of HIV care with other important health services, including hepatitis C, substance abuse and mental health treatment, and management of reproductive/maternal/child health, non-communicable diseases and tuberculosis.

Differentiated service delivery and care: What really is different?
A panel of health ministries’ representatives, researchers, policymakers, implementers and civil society describe the current state of affairs related to the uptake and implementation of differentiated service delivery and care policies.

The new $90-$90-$90: Drugs affordable for all
If treatments were priced at US$90 or less a year, a major treatment access barrier – cost – would be removed. This multi-perspective session discusses and analyses the barriers to global affordable drug pricing.

Transgender populations: Connecting the dots for trans clinical care services and HIV care
This session is aimed at healthcare providers, including clinicians, nurses and pharmacists, researchers, transgender individuals and community advocates. It discusses the issues surrounding care for trans populations who are also affected by HIV.

mHealth and the global HIV response: Harnessing the promise of mobile technologies for effective programme implementation
This session addresses mobile health (mHealth) technologies and social media platforms that are underused to support HIV prevention, increase access to HIV care, decrease healthcare costs, and empower users from science, community and policy perspectives.

HIV drug resistance and antimicrobial resistance: Science and action
A panel of health ministries’ representatives, researchers, modellers and policymakers describe the country-level evidence leading to the new WHO HIV Drug Resistance Global Action Plan and recommendations for a public health response.

Hepatitis C cure: Reality for few and dream for many
Hepatitis C virus (HCV) complicates the management of HIV and affects the response to ART. The availability of effective HCV treatment, with high cure rates for all genotypes, offers unprecedented opportunities. However, there are barriers, including high treatment costs, health service delivery issues, insufficient HCV screening programmes and limited HCV prevalence data.

Women’s health and HIV: Addressing challenges across the life cycle
This session will facilitate a discussion on the evidence and best practices related to supporting and empowering women across their life cycle – from infancy through adulthood.

Changing landscapes, changing gears: Differentiated service delivery for adolescents living with HIV
This workshop addresses the particular needs of adolescents living with HIV. Participants will learn about the role of peers in providing psychosocial support, discuss the necessities of differentiated service provision for this population, and hear from young people about what they want.

Plenary sessions on HIV treatment and care
Professor Wafaa El-Sadr (United States) on priority programmes for people living with HIV; Associate Professor Alexandra Calmy (Switzerland) on antiretroviral therapy and beyond.


| Return

Contact the Media Team

[email protected]